Impact of COVID-19 vaccination on hospitalization, hospital utilization and expenditure for COVID-19: A retrospective cohort analysis of a South African private health insured population.

Publication date: Jan 24, 2025

This study quantifies the impact of COVID-19 vaccination on hospitalization for COVID-19 infection in a South African private health insurance population. This retrospective cohort study is based on the analysis of demographic and claims records for 550,332 individuals belonging to two health insurance funds between 1 March 2020 and 31 December 2022. A Cox Proportional Hazards model was used to estimate the impact of vaccination (non-vaccinated, partly vaccinated, fully vaccinated) on COVID-19 hospitalization risk; and zero-inflated negative binomial models were used to estimate the impact of vaccination on hospital utilization and hospital expenditure for COVID-19 infection, with adjustments for age, sex, comorbidities and province of residence. In comparison to the non-vaccinated, the hospitalization rate for COVID-19 was 94. 51% (aHR 0. 06, 95%CI 0. 06, 0. 07) and 93. 49% (aHR 0. 07, 95%CI 0. 06, 0. 07) lower for the partly and fully vaccinated respectively; hospital utilization was 17. 70% (95% CI 24. 78%, 9. 95%) and 20. 04% (95% CI 28. 26%, 10. 88%) lower; the relative risk of zero hospital days was 4. 34 (95% CI 4. 02, 4. 68) and 18. 55 (95% CI 17. 12, 20. 11) higher; hospital expenditure was 32. 83% (95% CI 41. 06%, 23. 44%) and 55. 29% (95% CI 61. 13%, 48. 57%) lower; and the relative risk of zero hospital expenditure was 4. 38 (95% CI 4. 06, 4. 73) and 18. 61 (95% CI 17. 18, 20. 16) higher for the partly and fully vaccinated respectively. Taken together, findings indicate that all measures of hospitalization for COVID-19 infection were significantly lower in the partly or fully vaccinated in comparison to the non-vaccinated. The use of real-world data and an aggregated level of analysis resulted in the study having several limitations. While the overall results may not be generalizable to other populations, the findings add to the evidence based on the impact of COVID-19 vaccination during the period of the pandemic.

Open Access PDF

Concepts Keywords
African Adolescent
December Adult
Pandemic Aged
Vaccinated Child
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
Female
Health Expenditures
Hospitalization
Humans
Infant
Insurance, Health
Male
Middle Aged
Retrospective Studies
SARS-CoV-2
South Africa
Vaccination
Young Adult

Semantics

Type Source Name
disease MESH COVID-19
disease MESH infection
disease MESH Long Covid
disease IDO history
disease IDO process
pathway REACTOME Reproduction
disease MESH Emergency
disease MESH morbidity
disease MESH comorbidity
disease MESH death
disease MESH cancers
disease MESH chronic renal disease
disease MESH cardiac failure
disease MESH diabetes mellitus
disease MESH hypertension
disease MESH hypothyroidism
disease MESH heart disease
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH frailty
drug DRUGBANK Trestolone
drug DRUGBANK Coenzyme M
drug DRUGBANK Aspartame
drug DRUGBANK Vorinostat
drug DRUGBANK Ranitidine
drug DRUGBANK Elm
disease MESH Respiratory Diseases
disease MESH Meningitis
disease MESH Communicable Diseases
pathway REACTOME Release
disease MESH tic
drug DRUGBANK Troleandomycin

Original Article

(Visited 1 times, 1 visits today)